The human chemokine receptor CCRL2 suppresses chemotaxis and invasion by blocking CCL2-induced phosphorylation of p38 MAPK in human breast cancer cells

Abstract The human chemokine receptor CCRL2 is a member of the atypical chemokine receptor family. CCRL2 is unable to couple with G-proteins and fails to induce classical chemokine signaling for the highly conserved DRYLAIV motif essential for signaling has been changed to QRYLVFL. We investigated whether CCRL2 is involved in the chemotaxis, invasion, and proliferation of human breast cancer cells. Firstly, expression of CCRL2 was determined in six breast cancer cell lines by real-time RT-PCR and Western blot. Then, we established stable cell lines overexpressing CCRL2 to explore the function of CCRL2 in chemotaxis and invasion by transwell assays, and the signaling downstream was further investigated. The effect of CCRL2 on proliferation was detected by colony formation assays and tumor xenograft study. We found that stable overexpression of CCRL2 in MDA-MB-231 and BT-549 cells attenuated the chemotaxis and invasion stimulated by its ligand CCL2. CCRL2 inhibits p38 MAPK (p38) phosphorylation and up-regulates the expression of E-cadherin. This effect was eliminated by the inhibitor of p38 MAPK. CCRL2 inhibited the growth of breast cancer cells in vitro and in vivo. Our results suggest that CCRL2 functions as a tumor suppressor in human breast cancer cells.

[1]  R. Zeillinger,et al.  Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCR , 2005, Breast Cancer Research and Treatment.

[2]  A. Nebreda,et al.  Roles of p38 MAPKs in invasion and metastasis. , 2012, Biochemical Society transactions.

[3]  Shin-Da Lee,et al.  P38 mitogen‐activated protein kinase pathways are involved in the hypertrophy and apoptosis of cardiomyocytes induced by Porphyromonas gingivalis conditioned medium , 2008, Cell biochemistry and function.

[4]  M. Rosenkilde,et al.  Biased and G Protein-Independent Signaling of Chemokine Receptors , 2014, Front. Immunol..

[5]  R. Nibbs,et al.  Immune regulation by atypical chemokine receptors , 2013, Nature Reviews Immunology.

[6]  J. Medema,et al.  Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame? , 2013, Cancer letters.

[7]  E. Borroni,et al.  Atypical chemokine receptors: from silence to sound. , 2013, Biochemical Society transactions.

[8]  Jenny Bain,et al.  BIRB796 Inhibits All p38 MAPK Isoforms in Vitro and in Vivo* , 2005, Journal of Biological Chemistry.

[9]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[10]  K. Anderson,et al.  p38 and a p38-Interacting Protein Are Critical for Downregulation of E-Cadherin during Mouse Gastrulation , 2006, Cell.

[11]  Ahmad Raza,et al.  Breast cancer: major risk factors and recent developments in treatment. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[12]  Hendrik Veelken,et al.  CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM‐B , 2010, Immunology.

[13]  Simi Ali,et al.  Chemokines: novel targets for breast cancer metastasis , 2007, Cancer and Metastasis Reviews.

[14]  C. Garlanda,et al.  Nonredundant role of CCRL2 in lung dendritic cell trafficking. , 2010, Blood.

[15]  S. Hilsenbeck,et al.  Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. , 2009, Cancer research.

[16]  Julia L. Gregory,et al.  Macrophage Migration Inhibitory Factor and CD74 Regulate Macrophage Chemotactic Responses via MAPK and Rho GTPase , 2011, The Journal of Immunology.

[17]  E. Mendonça,et al.  E-cadherin as a potential biomarker of malignant transformation in oral leukoplakia: a retrospective cohort study , 2014, BMC Cancer.

[18]  M. Burger,et al.  Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia , 2010, Molecular Cancer.

[19]  S. Galli,et al.  Mast cell–expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis , 2008, The Journal of experimental medicine.

[20]  H. Boddeke,et al.  Expression of L‐CCR in HEK 293 cells reveals functional responses to CCL2, CCL5, CCL7, and CCL8 , 2003, Journal of leukocyte biology.

[21]  B. Lokeshwar,et al.  Chemokines and chemokine receptors as promoters of prostate cancer growth and progression. , 2013, Critical reviews in eukaryotic gene expression.

[22]  Jinghang Zhang,et al.  CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.

[23]  I. McInnes,et al.  Atypical chemokine receptors in inflammatory disease. , 2009, Current molecular medicine.

[24]  M. Miyasaka,et al.  Chemokines in tumor progression and metastasis , 2005, Cancer science.

[25]  T. Hielscher,et al.  The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis , 2016, Tumor Biology.

[26]  Christian Haslinger,et al.  p38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathway , 2007, Nature Genetics.

[27]  A. Mantovani,et al.  CCRL2, a fringe member of the atypical chemoattractant receptor family , 2013, European journal of immunology.

[28]  Marie C. M. Lin,et al.  Elevated chemokine CC-motif receptor-like 2 (CCRL2) promotes cell migration and invasion in glioblastoma. , 2012, Biochemical and biophysical research communications.

[29]  D. Gruol,et al.  The chemokine CCL2 activates p38 mitogen-activated protein kinase pathway in cultured rat hippocampal cells , 2008, Journal of Neuroimmunology.

[30]  A. Ghaderi,et al.  Expression of chemokines and chemokine receptors in brain tumor tissue derived cells. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[31]  Maria H. Ulvmar,et al.  Atypical chemokine receptors , 2011, Experimental cell research.

[32]  K. Schmeichel.  A fly's eye view of tumor progression and metastasis , 2004, Breast Cancer Research.

[33]  S. Koul,et al.  Role of p38 MAP Kinase Signal Transduction in Solid Tumors. , 2013, Genes & cancer.